ArticleBMC cancer2018

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Frédérique Penault-Llorca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.